BioCentury | Sep 6, 2019
Company News

Management tracks: Prometheus, Step, Spero, NorthSea, Aristea, MODAG and more

Salix’s Mark McKenna will become CEO of gastroenterology and autoimmune disease company Prometheus Biosciences Inc. (San Diego, Calif.), formerly known as Precision IBD Inc. McKenna was president at Salix Pharmaceuticals Ltd., a subsidiary of Bausch...
BioCentury | Dec 14, 2018
Finance

Spreading good Kurma

Declaring its last fund’s preseed partnership approach a success, Kurma Partners S.A. is expanding its model to build more new companies across Europe through its new Biofund III. For its 2016 Biofund II, the VC...
BioCentury | Dec 14, 2018
Financial News

Kurma announces first close of €150 million Biofund III

Kurma Partners S.A. completed the first close of its third fund, Kurma Biofund III, which is targeting a final close of €150 million ($169.4 million) in 2019. The firm declined to disclose the size of...
BioCentury | Jul 6, 2018
Finance

Dynacure’s quick transfer

A new €47 million ($54.7 million) round will allow Dynacure S.A.S. to begin clinical testing of its lead program to treat centronuclear myopathy (CNM) less than three years after its inception. The round is also...
BioCentury | Dec 1, 2017
Financial News

Step Pharma adds €8.6M to series A

Autoimmune play Step Pharma S.A.S. (Paris, France) raised €8.6 million ($10.2 million) in the second and final close of a series A round, bringing the total to €14.5 million ($17.1 million). New investor Pontifax Group...
BioCentury | Nov 21, 2017
Financial News

Step Pharma adds €8.6M to series A

Autoimmune play Step Pharma S.A.S. (Paris, France) raised €8.6 million ($10.2 million) in the second and final close of a series A round, bringing the total to €14.5 million ($17.1 million). New investor Pontifax Group...
BioCentury | May 25, 2017
Finance

Europe’s translational springtime

European science is showing early signs of translational growth, with VCs increasingly shifting their focus to preclinical assets. But investors are concerned the region still doesn’t have the supply of management talent or funding it...
BioCentury | Feb 16, 2017
Emerging Company Profile

Autoimmunity alternative

Inhibiting the nucleotide biosynthetic pathway in autoimmune diseases is one way to avoid the risks of broad immunosuppression, but the marketed compounds have serious side effects of their own. Step Pharma is pursuing a safer...
BioCentury | Jan 19, 2017
Finance

Kurma chameleon

French life science VC Kurma Partners S.A. is experimenting with a new investment model to accelerate the transfer of European academic research into the commercial setting with less risk than standard seed investments. The firm...
Items per page:
1 - 9 of 9
BioCentury | Sep 6, 2019
Company News

Management tracks: Prometheus, Step, Spero, NorthSea, Aristea, MODAG and more

Salix’s Mark McKenna will become CEO of gastroenterology and autoimmune disease company Prometheus Biosciences Inc. (San Diego, Calif.), formerly known as Precision IBD Inc. McKenna was president at Salix Pharmaceuticals Ltd., a subsidiary of Bausch...
BioCentury | Dec 14, 2018
Finance

Spreading good Kurma

Declaring its last fund’s preseed partnership approach a success, Kurma Partners S.A. is expanding its model to build more new companies across Europe through its new Biofund III. For its 2016 Biofund II, the VC...
BioCentury | Dec 14, 2018
Financial News

Kurma announces first close of €150 million Biofund III

Kurma Partners S.A. completed the first close of its third fund, Kurma Biofund III, which is targeting a final close of €150 million ($169.4 million) in 2019. The firm declined to disclose the size of...
BioCentury | Jul 6, 2018
Finance

Dynacure’s quick transfer

A new €47 million ($54.7 million) round will allow Dynacure S.A.S. to begin clinical testing of its lead program to treat centronuclear myopathy (CNM) less than three years after its inception. The round is also...
BioCentury | Dec 1, 2017
Financial News

Step Pharma adds €8.6M to series A

Autoimmune play Step Pharma S.A.S. (Paris, France) raised €8.6 million ($10.2 million) in the second and final close of a series A round, bringing the total to €14.5 million ($17.1 million). New investor Pontifax Group...
BioCentury | Nov 21, 2017
Financial News

Step Pharma adds €8.6M to series A

Autoimmune play Step Pharma S.A.S. (Paris, France) raised €8.6 million ($10.2 million) in the second and final close of a series A round, bringing the total to €14.5 million ($17.1 million). New investor Pontifax Group...
BioCentury | May 25, 2017
Finance

Europe’s translational springtime

European science is showing early signs of translational growth, with VCs increasingly shifting their focus to preclinical assets. But investors are concerned the region still doesn’t have the supply of management talent or funding it...
BioCentury | Feb 16, 2017
Emerging Company Profile

Autoimmunity alternative

Inhibiting the nucleotide biosynthetic pathway in autoimmune diseases is one way to avoid the risks of broad immunosuppression, but the marketed compounds have serious side effects of their own. Step Pharma is pursuing a safer...
BioCentury | Jan 19, 2017
Finance

Kurma chameleon

French life science VC Kurma Partners S.A. is experimenting with a new investment model to accelerate the transfer of European academic research into the commercial setting with less risk than standard seed investments. The firm...
Items per page:
1 - 9 of 9